Cargando…
Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension
Pulmonary arterial hypertension is a progressive disease that can lead to right-sided ventricular failure and premature death. Tailoring therapy to individual patient’s needs, along with regular risk assessment, is integral for optimal outcomes in patients with pulmonary arterial hypertension. Resul...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052464/ https://www.ncbi.nlm.nih.gov/pubmed/32166019 http://dx.doi.org/10.1177/2045894020910098 |
_version_ | 1783502879441551360 |
---|---|
author | Sahay, Sandeep Rahaghi, Franck |
author_facet | Sahay, Sandeep Rahaghi, Franck |
author_sort | Sahay, Sandeep |
collection | PubMed |
description | Pulmonary arterial hypertension is a progressive disease that can lead to right-sided ventricular failure and premature death. Tailoring therapy to individual patient’s needs, along with regular risk assessment, is integral for optimal outcomes in patients with pulmonary arterial hypertension. Results from the AMBITION trial support the use of upfront combination of tadalafil and ambrisentan. In a recent analysis of risk assessment in pulmonary arterial hypertension, abridged versions of the REVEAL 2.0 risk score were shown to be comparable to the full tools. In this report, we present a case series of the use of riociguat in upfront combination or sequentially, and the impact on risk scores as determined by the abridged REVEAL Lite 2.0 approach. |
format | Online Article Text |
id | pubmed-7052464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-70524642020-03-12 Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension Sahay, Sandeep Rahaghi, Franck Pulm Circ Case Series Pulmonary arterial hypertension is a progressive disease that can lead to right-sided ventricular failure and premature death. Tailoring therapy to individual patient’s needs, along with regular risk assessment, is integral for optimal outcomes in patients with pulmonary arterial hypertension. Results from the AMBITION trial support the use of upfront combination of tadalafil and ambrisentan. In a recent analysis of risk assessment in pulmonary arterial hypertension, abridged versions of the REVEAL 2.0 risk score were shown to be comparable to the full tools. In this report, we present a case series of the use of riociguat in upfront combination or sequentially, and the impact on risk scores as determined by the abridged REVEAL Lite 2.0 approach. SAGE Publications 2020-02-28 /pmc/articles/PMC7052464/ /pubmed/32166019 http://dx.doi.org/10.1177/2045894020910098 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Series Sahay, Sandeep Rahaghi, Franck Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension |
title | Real-world experience using combination therapy with riociguat and
risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial
hypertension |
title_full | Real-world experience using combination therapy with riociguat and
risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial
hypertension |
title_fullStr | Real-world experience using combination therapy with riociguat and
risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial
hypertension |
title_full_unstemmed | Real-world experience using combination therapy with riociguat and
risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial
hypertension |
title_short | Real-world experience using combination therapy with riociguat and
risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial
hypertension |
title_sort | real-world experience using combination therapy with riociguat and
risk assessment using reveal lite 2.0 in patients with pulmonary arterial
hypertension |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052464/ https://www.ncbi.nlm.nih.gov/pubmed/32166019 http://dx.doi.org/10.1177/2045894020910098 |
work_keys_str_mv | AT sahaysandeep realworldexperienceusingcombinationtherapywithriociguatandriskassessmentusingreveallite20inpatientswithpulmonaryarterialhypertension AT rahaghifranck realworldexperienceusingcombinationtherapywithriociguatandriskassessmentusingreveallite20inpatientswithpulmonaryarterialhypertension |